Den Europæiske Union - kroatisk - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Den Europæiske Union - kroatisk - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotska sredstva - prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 za hemodinamski nestabilne ТЭЛА pacijenata). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Den Europæiske Union - kroatisk - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotska sredstva - xarelto, uvedene zajedno sa ацетилсалициловой kiselinom (ask) sami ili sa asc plus клопидогрел ili Тиклопидин, prikazana za prevenciju атеротромботических događaja kod odraslih pacijenata nakon akutnog koronarni sindrom (acs) s povišenom razinom кардиальных biomarkera. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Kroatien - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - rosuvastatinkalcij acetilsalicilatna kiselina - kapsula, tvrda - 10 mg + 100 mg - urbroj: jedna tvrda kapsula sadrži 10 mg rosuvastatina (u obliku rosuvastatin kalcija) i 100 mg acetilsalicilatne kiseline

Kroatien - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - rosuvastatinkalcij acetilsalicilatna kiselina - kapsula, tvrda - 20 mg + 100 mg - urbroj: jedna tvrda kapsula sadrži 20 mg rosuvastatina (u obliku rosuvastatin kalcija) i 100 mg acetilsalicilatne kiseline

Kroatien - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - rosuvastatinkalcij acetilsalicilatna kiselina - kapsula, tvrda - 5 mg + 100 mg - urbroj: jedna tvrda kapsula sadrži 5 mg rosuvastatina (u obliku rosuvastatin kalcija) i 100 mg acetilsalicilatne kiseline

Bosnien-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

galenika d.o.o. - acetilsalicilna kiselina - tableta - 300 mg/1 tableta - jedna tableta sadrži: 300 mg acetilsalicilna kiselina

Bosnien-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pliva d.o.o.sarajevo - acetilsalicilna kiselina - tableta - 300 mg/1 tableta - 1 tableta sadrži: 300 mg acetilsalicilna kiselina

Bosnien-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - acetilsalicilna kiselina - gastrorezistentna tableta - 100 mg/1 tableta - 1 gastrorezistentna tableta sadrži: 100 mg acetilsalicilna kiselina

Montenegro - kroatisk - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - acetilsalicilna kiselina, askorbinska kiselina - Šumeća tableta - 800mg + 480mg